MGI MGISEQ-T7, MGISP-960, stLFR Library Prep Kit, MegaBolt Somatic
MGI, a subsidiary of the BGI Group, has launched the MGISEQ-T7 sequencing platform, The instrument can take up to four flow cells per run, which can be operated independently of each other. The platform, which supports whole genome sequencing, deep exome sequencing, epigenetic sequencing, and panel sequencing, generates up to 6 terabases of data per day. A run with 150-base paired-end reads takes less than 24 hours, and one instrument can sequence up to 10,000 human genomes per year.
MGI also launched the MGISP-960, an automated sample preparation system that can prepare 96 samples per run. In addition, it said that a new library preparation kit for single-tube Long Fragment Read (stLFR) technology will be commercially available in December. Finally, the company announced MegaBolt Somatic, an extended application for tumor mutation detection based on the MegaBolt bioinformatics accelerator. For more on the new BGI sequencing platform, click here.
Lucence Diagnostics LiquidHallMark
Lucence Diagnostics launched the LiquidHallMark blood test for detecting multiple cancer-related mutations and viral targets for clinical use in Asia. Physicians can use the test to select targeted therapies and to monitor treatment response. The liquid biopsy panel identifies clinically relevant genomic alterations including somatic mutations, microsatellite instability, and viral DNA from ctDNA in blood. It was developed for cancers that are particularly prevalent in Asia, such as breast, colon, lung, and nasopharyngeal cancers. The test is based on Lucence's proprietary technology called AmpliMark that has sensitivity and specificity of up to 99.9 percent, the company said.
SeraCare NTRK Reference Material Panel
SeraCare Life Sciences has announced the commercial launch of an expanded neurotrophic tropomyosin receptor kinase (NTRK) RNA fusion material panel developed in partnership with Bayer. The panel contains 15 clinically significant RNA fusions across the NTRK1, NTRK 2, and NTRK3 genes, and can be used by clinical labs to validate their detection by next-generation sequencing methods. The firm said that the RNA fusions are present within its reference cell line GM24385, and are formalin-fixed and paraffin embedded to represent typical processed tumor sections.
For more new products and services, please visit the New Products page on our website.